3 Wind Turbines Maker, Pharmaceutical Chemicals Company and Cement Maker Stocks With a Strong Future Roadmap: Suzlon Energy, Acutaas Chemicals and JK Cement

Wind turbine, pharma chemical and cement stocks let investors follow companies that serve a growing part of the Indian economy. Suzlon Energy, Acutaas Chemicals and JK Cement cover a wind turbines maker, a pharmaceutical chemicals company and a cement maker.

This list covers three wind turbine, pharma chemical and cement stocks with complete current figures: Suzlon Energy, Acutaas Chemicals and JK Cement. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Wind Turbine, Pharma Chemical and Cement Stocks?

Wind turbine, pharma chemical and cement stocks are listed companies that build wind turbines and offer wind farm services, make active pharmaceutical ingredients and intermediates, and produce grey and white cement. Their earnings depend on renewable capacity additions, pharma sourcing and construction activity.

Wind Turbine, Pharma Chemical and Cement Stocks at a Glance

On valuation, Suzlon Energy trades at a P/E below the industry P/E, while Acutaas Chemicals and JK Cement trade above it, which reflects the growth the market already expects. Readers comparing wind turbine, pharma chemical and cement stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Wind Turbine, Pharma Chemical and Cement Stocks Have a Strong Roadmap in India?

Wind turbine, pharma chemical and cement stocks have a strong roadmap in India because rapid renewable capacity additions, steady demand for generic medicines and heavy housing and infrastructure building keep widening the market for these companies.

• Wind power. Utilities add clean energy capacity.
• Pharma chemicals. Drug makers need dependable inputs.
• Cement. Housing and roads need steady supply.

Why Suzlon Energy Features Among These Wind Turbine, Pharma Chemical and Cement Stocks

Among the wind turbine, pharma chemical and cement stocks on this list, Suzlon Energy is a wind turbine maker with manufacturing and service operations across India, supplying turbines for utility, independent power producer and corporate customers and servicing a large installed base.

In the June 2026 quarter, revenue grew 22.0% year on year to Rs 3,863 crore. Revenue rose from Rs 6,604 crore in FY22 to Rs 16,842 crore in FY26, a compound annual growth rate of 26.4%.

Net profit grew from Rs 2,072 crore in FY25 to Rs 3,163 crore in FY26, a rise of 52.7%. The company has a return on equity of 33.4%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 55,008 crore. The stock trades at a P/E of 17.5, below the industry P/E of 43.9.

Roadmap: The company has a large order book and a strong share of the domestic wind market as the country adds renewable capacity. Its operations and maintenance business generates recurring income from the installed fleet.

What to watch: Check order book conversion to revenue and the pace of turbine deliveries each quarter.

Why Acutaas Chemicals Features Among These Wind Turbine, Pharma Chemical and Cement Stocks

Among the wind power, drug intermediate and building material shares on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.

The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.

Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.

Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.

What to watch: Follow capacity additions, new product approvals and export orders.

Why JK Cement Features Among These Wind Turbine, Pharma Chemical and Cement Stocks

Among the three companies on this list, JK Cement is a cement and building products company with plants in northern, western and southern India. It sells grey cement, white cement and wall putty, and it has a strong presence in the premium white cement segment.

Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%.

In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1.

Roadmap: The company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.

What to watch: Track capacity additions, volume growth and realisation per tonne.

Suzlon Energy vs Acutaas Chemicals vs JK Cement on Key Financials

The table below sets the three wind turbine, pharma chemical and cement stocks side by side on revenue, profit and margin, using reported figures.

Suzlon Energy posts the highest return on equity in this group at 33.4%. Suzlon Energy has the largest FY26 revenue at Rs 16,842 crore, and Acutaas Chemicals shows the fastest revenue growth with a 27.5% compound annual rate. A useful habit with wind turbine, pharma chemical and cement stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Wind Turbine, Pharma Chemical and Cement Stocks

Every theme carries risks that deserve a check before any decision. For these wind turbine, pharma chemical and cement stocks, the main points are: Long-term wind power, drug intermediate and building material shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Module prices. Solar equipment prices and policy support can change returns.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Fuel and power prices. Tariffs and fuel costs can influence earnings.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter wind turbine, pharma chemical and cement stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Wind Turbine, Pharma Chemical and Cement Stocks

Wind turbine, pharma chemical and cement stocks reward investors who follow demand trends, order books and margins together. Suzlon Energy, Acutaas Chemicals and JK Cement each have a clear plan to grow. Based on the 10 November 2026 close, Suzlon Energy trades at Rs 38.91, Acutaas Chemicals at Rs 3,882.6 and JK Cement at Rs 5,052.4.

Download the Univest iOS App or Univest Android App to track wind turbine, pharma chemical and cement stocks, set price alerts and get research-backed stock ideas.

What are wind turbine, pharma chemical and cement stocks?

Ans. Wind turbine, pharma chemical and cement stocks are listed companies that build wind turbines and offer wind farm services, make active pharmaceutical ingredients and intermediates, and produce grey and white cement. Their earnings depend on renewable capacity additions, pharma sourcing and construction activity. This list looks at three of them, Suzlon Energy, Acutaas Chemicals and JK Cement, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.

Which wind turbine, pharma chemical and cement stocks are covered in this list?

Ans. This list covers Suzlon Energy, Acutaas Chemicals and JK Cement. Based on the 10 November 2026 close, Suzlon Energy traded at Rs 38.91, Acutaas Chemicals at Rs 3,882.6 and JK Cement at Rs 5,052.4. Their return on equity ranges from 14.1% to 33.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.4% to 27.5%.

Why do wind turbine, pharma chemical and cement stocks have a strong future roadmap in India?

Ans. Wind turbine, pharma chemical and cement stocks have a strong roadmap in India because rapid renewable capacity additions, steady demand for generic medicines and heavy housing and infrastructure building keep widening the market for these companies. The main drivers are as follows. Wind power. Utilities add clean energy capacity. Pharma chemicals. Drug makers need dependable inputs. Cement. Housing and roads need steady supply. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Suzlon Energy performed financially?

Ans. Revenue rose from Rs 6,604 crore in FY22 to Rs 16,842 crore in FY26, a compound annual growth rate of 26.4%. Net profit grew from Rs 2,072 crore in FY25 to Rs 3,163 crore in FY26, a rise of 52.7%. In the June 2026 quarter, revenue grew 22.0% year on year to Rs 3,863 crore. The company has a return on equity of 33.4%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 55,008 crore. The stock trades at a P/E of 17.5, below the industry P/E of 43.9. Looking ahead, the company has a large order book and a strong share of the domestic wind market as the country adds renewable capacity. Its operations and maintenance business generates recurring income from the installed fleet.

How has Acutaas Chemicals performed financially?

Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.

How has JK Cement performed financially?

Ans. Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1. Looking ahead, the company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.

What risks should investors check before buying wind turbine, pharma chemical and cement stocks?

Ans. Investors should check a few risks before buying wind turbine, pharma chemical and cement stocks. Module prices. Solar equipment prices and policy support can change returns. Regulatory approvals. Plant inspections and approvals can affect supplies. Fuel and power prices. Tariffs and fuel costs can influence earnings. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of wind turbine, pharma chemical and cement stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.